Yakup Ergün· @dr_yakupergun · X·· 1 天前评分70
正文 · 原文
#ESMO26 | VOLGA
Neoadjuvant EV + perioperative durvalumab demonstrated impressive results in MIBC✅
An important detail: Approximately 25% of patients were not cisplatin-ineligible but had refused cisplatin.
Therefore, the potential role of this regimen may extend beyond cisplatin-ineligible patients
261 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org#ESMO26 | VOLGA | Presidential Symposium-1 In cisplatin-ineligible/refusing MIBC, neoadjuvant EV + perioperative durvalumab significantly improved EFS and OS vs the control arm. EFS: HR 0.55 (24-month: 78% vs 69%) OS: HR 0.58 (24-month: 83% vs 75%) pCR: 45% vs 10% Impressive results! Unlike KEYNOTE-905/EV-303, EV was administered only in the neoadjuvant setting, with no adjuvant EV. I’m looking forward to the discussion during the session.在 X 查看被引用的帖子
来源：Yakup Ergün · x.com